MDGL
HealthcareMadrigal Pharmaceuticals, Inc.
$446.27+7.54 (+1.72%)
Prev Close
$438.73
Open
$440.64
High
$448.07
Low
$434.30
Volume
144.4K
Market Cap
$9.67B
P/E
—
Div Yield
—
Over the past 12 months, insider activity at Madrigal Pharmaceuticals, Inc. (MDGL) has been exclusively selling, with 0 insider purchases totaling $0.00 and 24 insider sales totaling $88.32M. The most recent insider transaction was by Dier Mardi (officer: EVP and CFO), who sold $680.1K worth of shares on Mar 6, 2026. Madrigal Pharmaceuticals, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $9.67B.
Buys (12M)
0
$0.00
Sells (12M)
24
$88.32M
Net Activity
Net Seller
$88.32M
Active Insiders
7
last 12 mo
MDGL Price Chart
MDGL Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 6, 2026↗ | Dier Mardi | officer: EVP and CFO | Sell | 1,582 | $429.88 | $680.1K | 13,826 |
| Mar 6, 2026↗ | Huntsman Carole | officer: Chief Commercial Officer | Sell | 419 | $431.94 | $181.0K | 12,692 |
| Mar 6, 2026↗ | Kelley Shannon T | officer: General Counsel | Sell | 360 | $431.94 | $155.5K | 12,138 |
| Mar 6, 2026↗ | Sibold William John | director, officer: President and CEO | Sell | 1,663 | $431.94 | $718.3K | 161,829 |
| Mar 6, 2026↗ | Taub Rebecca | director | Sell | 491 | $431.94 | $212.1K | 452,213 |
| Mar 2, 2026↗ | Dier Mardi | officer: EVP and CFO | Sell | 1,183 | $427.21 | $505.4K | 9,257 |
| Jan 26, 2026↗ | Huntsman Carole | officer: Chief Commercial Officer | Sell | 1,820 | $493.78 | $898.7K | 9,692 |
| Jan 26, 2026↗ | Sibold William John | President and CEO | Sell | 3,154 | $492.42 | $1.55M | 148,497 |
| Jan 26, 2026↗ | Taub Rebecca | Director | Sell | 1,294 | $492.42 | $637.2K | 452,704 |
| Jan 20, 2026↗ | Kelley Shannon T | officer: General Counsel | Sell | 692 | $497.36 | $344.2K | 8,910 |
| Jan 20, 2026↗ | Taub Rebecca | Director | Sell | 4,476 | $490.77 | $2.20M | 453,351 |
| Jan 13, 2026↗ | FRIEDMAN PAUL A | director | Sell | 24,440 | $522.59 | $12.77M | 210,204 |
| Jan 13, 2026↗ | Taub Rebecca | director | Sell | 17,170 | $522.81 | $8.98M | 473,039 |
| Jan 9, 2026↗ | FRIEDMAN PAUL A | Director | Sell | 280 | $551.24 | $154.3K | 0 |
| Jan 9, 2026↗ | Taub Rebecca | Director | Sell | 240 | $550.33 | $132.1K | 0 |
| Dec 10, 2025↗ | FRIEDMAN PAUL A | Director | Sell | 24,800 | $552.19 | $13.69M | 0 |
| Dec 3, 2025↗ | Sibold William John | President and CEO | Sell | 2,400 | $575.34 | $1.38M | 0 |
| Nov 21, 2025↗ | Huntsman Carole | Chief Commercial Officer | Sell | 1,958 | $553.11 | $1.08M | 0 |
| Nov 5, 2025↗ | BATE KENNETH | Director | Sell | 16,575 | $484.30 | $8.03M | 0 |
| Aug 21, 2025↗ | Sibold William John | President and CEO | Sell | 7,616 | $400.18 | $3.05M | 0 |
| Aug 15, 2025↗ | BATE KENNETH | Director | Sell | 10,000 | $365.20 | $3.65M | 0 |
| Aug 11, 2025↗ | FRIEDMAN PAUL A | Director | Sell | 46,808 | $355.31 | $16.63M | 0 |
| Jul 18, 2025↗ | FRIEDMAN PAUL A | Director | Sell | 1,400 | $350.03 | $490.0K | 0 |
| Jul 16, 2025↗ | FRIEDMAN PAUL A | Director | Sell | 28,876 | $353.19 | $10.20M | 0 |
| Mar 10, 2025↗ | Dier Mardi | SVP and CFO | Sell | 258 | $323.04 | $83.3K | 0 |
| Mar 3, 2025↗ | Huntsman Carole | Chief Commercial Officer | Sell | 1,834 | $325.98 | $597.8K | 0 |
| Feb 27, 2025↗ | BATE KENNETH | Director | Sell | 20,000 | $356.44 | $7.13M | 0 |
| Jan 27, 2025↗ | Huntsman Carole | Chief Commercial Officer | Sell | 347 | $335.24 | $116.3K | 10,438 |
| Jan 27, 2025↗ | Sibold William John | President and CEO | Sell | 1,584 | $335.24 | $531.0K | 54,303 |
| Jan 27, 2025↗ | Taub Rebecca | Pres., R&D, and CMO | Sell | 648 | $335.24 | $217.2K | 456,662 |
| Jan 27, 2025↗ | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sell | 103 | $335.24 | $34.5K | 4,955 |
| Jan 17, 2025↗ | Kelley Shannon T | General Counsel | Sell | 277 | $273.41 | $75.7K | 7,705 |
| Jan 17, 2025↗ | Taub Rebecca | Pres., R&D, and CMO | Sell | 1,689 | $273.41 | $461.8K | 457,310 |
| Jan 17, 2025↗ | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sell | 442 | $273.41 | $120.8K | 5,058 |
| Dec 5, 2024↗ | CRAVES FRED B | Director | Sell | 3,600 | $315.31 | $1.14M | 11,520 |
| Nov 27, 2024↗ | CRAVES FRED B | Director | Sell | 3,400 | $350.30 | $1.19M | 15,800 |
| Nov 22, 2024↗ | Huntsman Carole | Chief Commercial Officer | Sell | 688 | $316.92 | $218.0K | 10,785 |
| Nov 8, 2024↗ | Levy Richard S | Sell | 5,000 | $350.00 | $1.75M | 11,012 | |
| Nov 5, 2024↗ | Levy Richard S | Sell | 5,000 | $300.94 | $1.50M | 13,212 | |
| Sep 11, 2024↗ | Sibold William John | President and CEO | Sell | 6,363 | $243.83 | $1.55M | 55,887 |
| Jun 18, 2024↗ | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sell | 1,900 | $280.00 | $532.0K | 5,500 |
| Jun 14, 2024↗ | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sell | 2,000 | $285.00 | $570.0K | 5,500 |
| May 23, 2024↗ | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sell | 1,036 | $231.34 | $239.7K | 5,500 |
| May 16, 2024↗ | CRAVES FRED B | Sell | 22,489 | $212.88 | $4.79M | 427,024 | |
| Apr 10, 2024↗ | FRIEDMAN PAUL A | Sell | 26,270 | $246.19 | $6.47M | 210,564 | |
| Apr 10, 2024↗ | Taub Rebecca | Pres., R&D, and CMO | Sell | 2,676 | $245.99 | $658.3K | 461,451 |
| Apr 5, 2024↗ | FRIEDMAN PAUL A | Director | Sell | 73,730 | $243.93 | $17.98M | 212,957 |
| Apr 5, 2024↗ | Taub Rebecca | Pres., R&D, and CMO | Sell | 73,888 | $243.92 | $18.02M | 486,709 |
| Apr 3, 2024↗ | BATE KENNETH | Director | Sell | 32,489 | $252.85 | $8.21M | 15,777 |
| Apr 3, 2024↗ | Daly James M | Director | Sell | 32,489 | $252.97 | $8.22M | 15,966 |
Showing 1–50 of 65
1 / 2
MDGL Insider Buying Activity
The following table shows recent insider purchases of Madrigal Pharmaceuticals, Inc. (MDGL) stock reported via SEC Form 4 filings.
No insider buying activity found for MDGL in the last 12 months.
MDGL Insider Selling Activity
The following table shows recent insider sales of Madrigal Pharmaceuticals, Inc. (MDGL) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 6, 2026↗ | Dier Mardi | officer: EVP and CFO | Sell | 1,582 | $429.88 | $680.1K | 13,826 |
| Mar 6, 2026↗ | Huntsman Carole | officer: Chief Commercial Officer | Sell | 419 | $431.94 | $181.0K | 12,692 |
| Mar 6, 2026↗ | Kelley Shannon T | officer: General Counsel | Sell | 360 | $431.94 | $155.5K | 12,138 |
| Mar 6, 2026↗ | Sibold William John | director, officer: President and CEO | Sell | 1,663 | $431.94 | $718.3K | 161,829 |
| Mar 6, 2026↗ | Taub Rebecca | director | Sell | 491 | $431.94 | $212.1K | 452,213 |
| Mar 2, 2026↗ | Dier Mardi | officer: EVP and CFO | Sell | 1,183 | $427.21 | $505.4K | 9,257 |
| Jan 26, 2026↗ | Huntsman Carole | officer: Chief Commercial Officer | Sell | 1,820 | $493.78 | $898.7K | 9,692 |
| Jan 26, 2026↗ | Sibold William John | President and CEO | Sell | 3,154 | $492.42 | $1.55M | 148,497 |
| Jan 26, 2026↗ | Taub Rebecca | Director | Sell | 1,294 | $492.42 | $637.2K | 452,704 |
| Jan 20, 2026↗ | Kelley Shannon T | officer: General Counsel | Sell | 692 | $497.36 | $344.2K | 8,910 |
| Jan 20, 2026↗ | Taub Rebecca | Director | Sell | 4,476 | $490.77 | $2.20M | 453,351 |
| Jan 13, 2026↗ | FRIEDMAN PAUL A | director | Sell | 24,440 | $522.59 | $12.77M | 210,204 |
| Jan 13, 2026↗ | Taub Rebecca | director | Sell | 17,170 | $522.81 | $8.98M | 473,039 |
| Jan 9, 2026↗ | FRIEDMAN PAUL A | Director | Sell | 280 | $551.24 | $154.3K | 0 |
| Jan 9, 2026↗ | Taub Rebecca | Director | Sell | 240 | $550.33 | $132.1K | 0 |
| Dec 10, 2025↗ | FRIEDMAN PAUL A | Director | Sell | 24,800 | $552.19 | $13.69M | 0 |
| Dec 3, 2025↗ | Sibold William John | President and CEO | Sell | 2,400 | $575.34 | $1.38M | 0 |
| Nov 21, 2025↗ | Huntsman Carole | Chief Commercial Officer | Sell | 1,958 | $553.11 | $1.08M | 0 |
| Nov 5, 2025↗ | BATE KENNETH | Director | Sell | 16,575 | $484.30 | $8.03M | 0 |
| Aug 21, 2025↗ | Sibold William John | President and CEO | Sell | 7,616 | $400.18 | $3.05M | 0 |
| Aug 15, 2025↗ | BATE KENNETH | Director | Sell | 10,000 | $365.20 | $3.65M | 0 |
| Aug 11, 2025↗ | FRIEDMAN PAUL A | Director | Sell | 46,808 | $355.31 | $16.63M | 0 |
| Jul 18, 2025↗ | FRIEDMAN PAUL A | Director | Sell | 1,400 | $350.03 | $490.0K | 0 |
| Jul 16, 2025↗ | FRIEDMAN PAUL A | Director | Sell | 28,876 | $353.19 | $10.20M | 0 |
| Mar 10, 2025↗ | Dier Mardi | SVP and CFO | Sell | 258 | $323.04 | $83.3K | 0 |
| Mar 3, 2025↗ | Huntsman Carole | Chief Commercial Officer | Sell | 1,834 | $325.98 | $597.8K | 0 |
| Feb 27, 2025↗ | BATE KENNETH | Director | Sell | 20,000 | $356.44 | $7.13M | 0 |
| Jan 27, 2025↗ | Huntsman Carole | Chief Commercial Officer | Sell | 347 | $335.24 | $116.3K | 10,438 |
| Jan 27, 2025↗ | Sibold William John | President and CEO | Sell | 1,584 | $335.24 | $531.0K | 54,303 |
| Jan 27, 2025↗ | Taub Rebecca | Pres., R&D, and CMO | Sell | 648 | $335.24 | $217.2K | 456,662 |
| Jan 27, 2025↗ | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sell | 103 | $335.24 | $34.5K | 4,955 |
| Jan 17, 2025↗ | Kelley Shannon T | General Counsel | Sell | 277 | $273.41 | $75.7K | 7,705 |
| Jan 17, 2025↗ | Taub Rebecca | Pres., R&D, and CMO | Sell | 1,689 | $273.41 | $461.8K | 457,310 |
| Jan 17, 2025↗ | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sell | 442 | $273.41 | $120.8K | 5,058 |
| Dec 5, 2024↗ | CRAVES FRED B | Director | Sell | 3,600 | $315.31 | $1.14M | 11,520 |
| Nov 27, 2024↗ | CRAVES FRED B | Director | Sell | 3,400 | $350.30 | $1.19M | 15,800 |
| Nov 22, 2024↗ | Huntsman Carole | Chief Commercial Officer | Sell | 688 | $316.92 | $218.0K | 10,785 |
| Nov 8, 2024↗ | Levy Richard S | Sell | 5,000 | $350.00 | $1.75M | 11,012 | |
| Nov 5, 2024↗ | Levy Richard S | Sell | 5,000 | $300.94 | $1.50M | 13,212 | |
| Sep 11, 2024↗ | Sibold William John | President and CEO | Sell | 6,363 | $243.83 | $1.55M | 55,887 |
| Jun 18, 2024↗ | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sell | 1,900 | $280.00 | $532.0K | 5,500 |
| Jun 14, 2024↗ | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sell | 2,000 | $285.00 | $570.0K | 5,500 |
| May 23, 2024↗ | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sell | 1,036 | $231.34 | $239.7K | 5,500 |
| May 16, 2024↗ | CRAVES FRED B | Sell | 22,489 | $212.88 | $4.79M | 427,024 | |
| Apr 10, 2024↗ | FRIEDMAN PAUL A | Sell | 26,270 | $246.19 | $6.47M | 210,564 | |
| Apr 10, 2024↗ | Taub Rebecca | Pres., R&D, and CMO | Sell | 2,676 | $245.99 | $658.3K | 461,451 |
| Apr 5, 2024↗ | FRIEDMAN PAUL A | Director | Sell | 73,730 | $243.93 | $17.98M | 212,957 |
| Apr 5, 2024↗ | Taub Rebecca | Pres., R&D, and CMO | Sell | 73,888 | $243.92 | $18.02M | 486,709 |
| Apr 3, 2024↗ | BATE KENNETH | Director | Sell | 32,489 | $252.85 | $8.21M | 15,777 |
| Apr 3, 2024↗ | Daly James M | Director | Sell | 32,489 | $252.97 | $8.22M | 15,966 |
MDGL Insiders
Similar Stocks to MDGL
VRTX
Vertex Pharmaceuticals Incorporated
$470.20-1.66%
$121.44B
REGN
Regeneron Pharmaceuticals, Inc.
$743.51-0.41%
$77.57B
ALNY
Alnylam Pharmaceuticals, Inc.
$313.45-1.19%
$42.07B
INSM
Insmed Incorporated
$139.06-0.33%
$30.07B
UTHR
United Therapeutics Corporation
$536.12+0.97%
$23.50B
MRNA
Moderna, Inc.
$52.56-1.89%
$20.76B
ROIV
Roivant Sciences Ltd.
$28.06-1.44%
$20.08B
RPRX
Royalty Pharma plc
$45.65-0.57%
$19.56B